Drug backer Sofinnova rounds up $500 mln for Fund IX

The late-stage life sciences investor reaches hard cap, exceeding its $425 million target

ByChris Witkowsky

23 July 2014•2 mins read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.